ScoreWhy is Keros Therapeutics, Inc. ?
1
With a fall in Net Sales of -99.83%, the company declared Very Negative results in Mar 26
- The company has declared negative results in Mar 26 after 5 consecutive negative quarters
- NET SALES(HY) At USD 0.75 MM has Grown at -99.65%
- PRE-TAX PROFIT(Q) At USD -23.71 MM has Fallen at -114.96%
- NET PROFIT(Q) At USD -23.71 MM has Fallen at -115.97%
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -20.06%, its profits have risen by 146.5% ; the PEG ratio of the company is 0
3
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -20.06% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Keros Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Keros Therapeutics, Inc.
-20.35%
-1.60
48.50%
S&P 500
20.78%
1.67
13.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
200.51%
EBIT Growth (5y)
28.10%
EBIT to Interest (avg)
-81.74
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.18
Tax Ratio
71.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0.14%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
5
Industry P/E
Price to Book Value
1.43
EV to EBIT
2.19
EV to EBITDA
2.15
EV to Capital Employed
8.18
EV to Sales
0.61
PEG Ratio
0.03
Dividend Yield
NA
ROCE (Latest)
373.25%
ROE (Latest)
28.73%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-25What is not working for the Company
NET SALES(HY)
At USD 0.75 MM has Grown at -99.65%
PRE-TAX PROFIT(Q)
At USD -23.71 MM has Fallen at -114.96%
NET PROFIT(Q)
At USD -23.71 MM has Fallen at -115.97%
RAW MATERIAL COST(Y)
Grown by 110.94% (YoY
DEBT-EQUITY RATIO
(HY)
Highest at -92.84 %
EPS(Q)
Lowest at USD -1.21
Here's what is not working for Keros Therapeutics, Inc.
Net Sales
At USD 0.75 MM has Grown at -99.65%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Pre-Tax Profit
At USD -23.71 MM has Fallen at -114.96%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -23.71 MM has Fallen at -115.97%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
EPS
Lowest at USD -1.21
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Highest at -92.84 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 110.94% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
